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Abstract
Symmetric aromatic diselenides are potential anticancer agents with strong cytotoxic activity. In this study, the in vitro anticancer activities of a
novel series of diarylseleno derivatives from the diphenyldiselenide (DPDS) scaffold were evaluated. Most of the compounds exhibited high effi-
cacy for inducing cytotoxicity against different human cancer cell lines. DPDS 2, the compound with the lowest mean GI50 value, induced both
caspase-dependent apoptosis and arrest at the G0/G1 phase in acute lymphoblastic leucemia CCRF-CEM cells. Consistent with this, PARP cleav-
age; enhanced caspase-2, -3, -8 and -9 activity; reduced CDK4 expression and increased levels of p53 were detected in these cells upon DPDS
2 treatment. Mutated p53 expressed in CCRF-CEM cells retains its transactivating activity. Therefore, increased levels of p21CIP1 and BAX pro-
teins were also detected. On the other hand, DPDS 6, the compound with the highest selectivity index for cancer cells, resulted in G2/M cell
cycle arrest and caspase-independent cell death in p53 deficient HTB-54 lung cancer cells. Autophagy inhibitors 3-methyladenine, wortmannin
and chloroquine inhibited DPDS 6-induced cell death. Consistent with autophagy, increased LC3-II and decreased SQSTM1/p62 levels were
detected in HTB-54 cells in response to DPDS 6. Induction of JNK phosphorylation and a reduction in phospho-p38 MAPK were also detected.
Moreover, the JNK inhibitor SP600125-protected HTB-54 cells from DPDS 6-induced cell death indicating that JNK activation is involved in
DPDS 6-induced autophagy. These results highlight the anticancer effects of these derivatives and warrant future studies examining their clinical
potential.
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Introduction
Epidemiological and experimental data indicate that selenium (Se)
protects against several types of cancer, including leucemia, breast,
colon, lung and prostate cancer [1–3]. Se provides antioxidant pro-
tection and disarms several hallmarks of cancer, such as deregulated
cancer metabolism, cancer-associated immunosuppression, regula-
tion of cell proliferation and tumour cell invasion and angiogenesis
[4]. In this context, a major challenge for chemical engineering has
been the development of novel Se-containing drugs for the treatment
of cancer. Thus, sodium selenite [5–8], methylseleninic acid [9],
selenomethionine [10], methylselenocarbamates [11] and bisacylimi-
doselenocarbamates [12] have been evaluated, among others, as
potential anticancer agents. A number of mechanisms, including
inhibition of tumour angiogenesis, cell cycle arrest [5, 10], apoptosis
induction [5, 13], modulation of autophagy [14] and mitotic catastro-
phe [12], account for the anticancer effects of these compounds.
Over the last years, crosstalk between distinct modes of cell
death, including autophagy and apoptosis, has been reported, and
p53 status has emerged as important for both of these modes of cell
death. Thus, whereas basal p53 activity suppresses autophagy, p53
activation by some stimuli induces both autophagy and apoptosis
[15, 16]. JNK and MAPK14 (p38a) signallings also regulate autop-
hagy [17]. Depending on the cell type and the nature of the stimulus,
JNK and p38a can mediate cell death or cell survival [18, 19]. For
instance, piperlongumine-induced autophagy in U2OS osteosarcoma
cells is dependent on the activation of the p38 pathway [20], whereas
inhibition of p38 phosphorylation is required for the induction of
apoptosis and autophagy by plumbaginin in PC-3 prostate cancer
cells [21]. On the other hand, JNK1 acts as a positive regulator of
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autophagy in non-neuronal cells, whereas inhibition of Bnip3 tran-
scription by neuronal JNK suppress autophagy [22]. Interestingly,
when testing sodium selenite in leucemia [5–7] and colorectal cancer
[23] cells, both p53 status of the cell and p38a phosphorylation have
been implicated in the switch from autophagy to apoptosis. In fact,
p38a phosphorylation promoted apoptosis and compromised autop-
hagy in NB4 leucemia cells [7]. On the other hand, selenite-mediated
p38a phosphorylation induced a marked autophagic response in p53-
deficient Jurkat cells [6]. Autophagy also occurred in both p53
expressing and p53-KO HCT-116 colorectal cancer cells exposed to
selenite. However, selenite-induced autophagy levels were higher in
the p53-KO cells [23].
Lung cancer is the leading cause of cancer death worldwide.
Approximately 80% of lung cancer cases are classified histologically
as non-small cell lung cancer (NSCLC) [24]. The p53 gene is inacti-
vated by mutation in greater than 50% of NSCLC patients, and p53
mutations are a statistically significant predictor of poor outcome in
patients with stage I NSCLC [24]. Interestingly, both autophagy and
apoptosis play a role in NSCLC progression, and p53-KO cells dis-
played enhanced autophagy compared with their wild-type counter-
parts [25]. Diphenyldiselenide (DPDS) is an active organoselenium
compound with antioxidant, neuroprotective and anti-inflammatory
properties [26]. DPDS exhibits cytotoxic activity against a number of
tumour cell lines [27, 28]. We aimed to analyse the anticancer poten-
tial of novel symmetrical diarylseleno derivatives from the DPDS scaf-
fold. Here, we demonstrate that DPDS 6, one such derivative, induced
cell cycle arrest and autophagy in p53-deficient NSCLC cells by mod-
ulating JNK and p38 MAPK activities.
Materials and methods
Materials
The synthesis of the compounds described in this work was performed
at the Department of Organic and Pharmaceutical Chemistry of the
University of Navarra. The synthesis was performed via a reaction
between 4,40-diaminodiphenyldiselenide and the appropriate isocyanate
(compounds DPDS 1–4), isothiocyanate (compounds DPDS 5–9) or
isoselenocyanate (compounds 10–13) in a 1:2 molar ratio, in dry diox-
ane. The final compounds were obtained at yields ranging from 2% to
75%. Isocyanates and isothiocyanates were commercially available, but
the corresponding isoselenocyanates were prepared in two steps by
formylation of amines followed by the treatment with phosgene and Se
powder in the presence of triethylamine under reflux. Each product was
identified by infrared, 1H-NMR and 13C-NMR spectroscopy, elemental
analysis and mass spectrometry.
Cell culture
Human cell lines were obtained from the American Type Culture Collec-
tion (ATCC; Manassas, VA, USA). CCRF-CEM (T-ALL), K-562 (chronic
myeloid leucemia), PC-3 (prostate carcinoma), HT-29 (colon carci-
noma), HTB-54 (lung carcinoma), MOLT-4 (T-ALL) and A549 (lung
carcinoma) cells were grown in RPMI 1640 (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% foetal bovine serum (FBS). MCF-7 (breast
adenocarcinoma) cells were grown in EMEM (ATCC) supplemented with
10% FBS. In addition, 184B5 (non-malignant, mammary-gland derived)
cells were grown in Hams F12/DMEM (50:50) supplemented as previ-
ously described [12]. BEAS-2B (non-malignant, derived from bronchial
epithelium) were grown in RPMI 1640 supplemented with 5% FBS, 19
insulin-transferrin-sodium selenite (ITS), 500 ng/ml hydrocortisone,
2 mM sodium pyruvate, 2 mM glutamine, 20 mg/ml penicillin/gentam-
icin, 20 ng/ml epidermal growth factor (EGF) and 0.3 nM retinoic acid.
Media were renewed every 2 days, and cells were subcultured at a ratio
of 1:3.
Cytotoxic and antiproliferative activities
Cytotoxicity was determined using the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide) method at five different doses
ranging from 0.01 to 100 lM, as previously described [12]. Briefly,
depending on the cell line, 8,000 to 40,000 cells/well were plated in 96-
well plates. Plates were incubated overnight at 37°C in a humidified
atmosphere containing 5% CO2. Then, the media were replaced by
media containing DPDSs at the appropriate concentration. DPDSs were
dissolved in DMSO at a concentration of 0.1 M, and 10-fold serial dilu-
tions were made from this stock using complete culture medium. To
measure the cell population at the time of drug addition, 20 ll of a
5 mg/ml solution of MTT in PBS was added to each well of one plate
with no DPDS added. After mixing, cells were incubated for 4 additional
hours to allow the MTT conversion into formazan. After incubation,
media were removed. Formazan was dissolved in 200 ll DMSO, and
optical density (time zero; A0) was read at 550 nm. Regarding plates
containing drugs, following drug addition, the plates were incubated for
an additional 72 hrs to allow the drug to take effect. After incubation,
20 ll of the MTT solution was added to each well, and plates were pro-
cessed as described above. Optical densities were thus obtained for
control cells (no drug added; Ac) and cells grown in the presence of
DPDS at the five concentration levels (test growth; Ai). Percentage
growth inhibition was then calculated as [(Ai  A0)/Ac  A0)] 9 100
when Ai ≥ A0 and [(Ai  A0)/A0)] 9 100 when Ai < A0. The results
were obtained from at least three independent experiments performed
in quadruplicate and expressed as GI50, which is the concentration that
results in 50% reduction in the growth of treated cells with respect to
untreated controls; and LC50, the concentration resulting in a 50%
reduction of the initial number of cells.
Cell cycle analysis and quantification of cell
death
Cell cycle analysis and quantification of cell death were conducted by
flow cytometry. For HTB-54 and A549 cells, the cell death status and
cell cycle analysis were determined using the Apo-Direct kit (BD
Pharmingen, BD Biosciences, Madrid, Spain) based on the TUNEL tech-
nique under the conditions described by the manufacturer. The apop-
totic status of leucemia CCRF-CEM and MOLT-4 cells was evaluated
using the Annexin V-FITC Kit (BD Pharmingen). For apoptosis and
autophagy inhibition experiments, cells were pre-incubated for 1 hr
in the absence or presence of 50 lM z-VAD-fmk, 10 lM wort-
mannin, 5 mM 3-methyladenine (3-MA) or 10 lM chloroquine (CQ)
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(Sigma-Aldrich, St. Louis, MO, USA). To assess the role of JNK, cells
were pre-treated for 1 hr with 10 lM SP600125 (Invivogen, San Diego,
CA, USA). For CCRF-CEM and MOLT-4 cell cycle analysis, cells were
fixed in 70% ethanol, and the DNA content of fixed cells was measured
by staining with propidium iodide.
Caspase activity determination
Caspase activities were assayed using the Apo Alert Caspase Assay
Plates (Clontech Laboratories, Mountain View, CA, USA) under the con-
ditions described by the manufacturer.
Protein analysis
Proteins were detected by Western blot. Anti-Actin (H-300), anti-Cdk-4
(C-22), anti-p53 (C-19) and anti-p21 (N-20) antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Specific antibod-
ies for PARP, BAX, p14 ARF (4C6/4), SQSTM1/p62, LC3, p38 MAPK,
Phospho-p38 MAPK (Thr180/Tyr182), SAPK/JNK and Phospho-SAPK
(Thr183/Tyr185) (G9) detection were obtained from Cell Signaling
Technology (Danvers, MA, USA). Anti-rabbit IgG, anti-goat IgG or anti-
mouse IgG conjugated with peroxidase were used as secondary anti-
bodies.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 software. The two-
tailed Student’s non-parametric t-test (Mann–Whitney U-test) was used
to compare non-normally distributed data from two groups. Differences
were considered significant at *P < 0.05, **P < 0.01 and
***P < 0.001.
Results
Cytotoxicity of the DPDS derivatives in human
cancer cell lines
The growth inhibitory activities of the thirteen DPDS-related com-
pounds, whose structures are shown in Figure 1, were deter-
mined in HTB-54, HT-29, MCF-7, PC-3, CCRF-CEM and K-562
cells. Assays were performed using the MTT method. The cyto-
toxic effect of each substance was tested at five different con-
centrations ranging from 0.01 to 100 lM. GI50, and LC50 values
were calculated from dose-response curves. Doxorubicin, camp-
tothecin, etoposide and cisplatin were used as positive controls.
As shown in Table 1, most of the tested compounds displayed
important in vitro anticancer activity. PC-3 and leucemia cell lines
were generally more sensitive to the cytotoxic effect of these
derivatives compared with colon and lung cancer cell lines. Fur-
thermore, most of the tested compounds displayed similar or
increased in vitro anticancer activity compared with the standard
chemotherapeutic agents cisplatin and etoposide. In fact, each
compound yielded reduced GI50 values compared with etoposide
in HT-29 and MCF-7 cells. DPDSs 1–8, 11 and 12 also produced
similar results in K-562 cells. In addition, DPDSs 2, 5 and 6 in
K-562 cells; DPDSs 1–7 and 47 in PC-3 cells; DPDSs 1, 3, 4
and 7 in HT-29 cells; and DPDSs 2 and 5–7 in HTB-54 cells
exhibited reduced GI50 values compared with cisplatin.
To determine the selectivity of these compounds for tumour
cells, cytotoxicity was also assessed in the non-malignant cell
lines 184B5 and BEAS-2B (Table 1). The selectivity index (SI) for
breast and lung cells was calculated from LC50 values according
to the formulas SI = LC50 (184B5)/LC50 (MCF-7) and LC50
(BEAS-2B)/LC50 (HTB-54). Interestingly, although most of the
analysed compounds exhibited low selectivity for malignant cells,
DPDS 6 exhibited a high selectivity for tumour cells in lung cul-
tures (LC50 BEAS-2B = 78.77 lM; LC50 HTB-54 = 10.31 lM;
SI = 7.63).
Fig. 1 Structure of the DPDS used in this work.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
291
J. Cell. Mol. Med. Vol 22, No 1, 2018
DPDS derivatives induce cell cycle arrest
Given that cell cycle regulation is involved in the therapeutic effects of
several Se-containing compounds [29, 30] we next analysed whether
the DPDS derivatives affected cell cycle progression. In these studies,
DPDS 2, the compound that yielded the lowest mean GI50 value
across all cell lines (ranging from 0.30 to 8.71 lM) in the panel, and
DPDS 6, the compound with the highest SI in lung cells, were chosen.
Given that T-ALL CCRF-CEM cells were the most sensitive cells
towards the majority of the tested compounds, DPDS 2 action on cell
cycle was assessed by determining the cell cycle phase distribution of
CCRF-CEM cells after treatment with different concentrations of DPDS
2 for 24 hrs. Determinations were performed by measuring the DNA
content of the cells by propidium iodide staining and flow cytometry.
Camptothecin was used as a positive control. Results are presented
in Figure 2A and B. According to the cytotoxic effects exerted by
DPDS 2, a significant increase in the hypodiploid SubG1 cell popula-
tion was detected after treatment with 2 lM or greater DPDS 2. Con-
sistent with cell cycle arrest at the G0/G1 phase, a significant increase
in the G0/G1 cell population accompanied by a significant reduction in
the percentage of cells in both G2/M and S phases was observed with
5 lM DPDS 2. Time course analysis of cell cycle distribution upon
treatment with 5 lM DPDS 2 confirmed G0/G1 cell cycle arrest at 24
and 48 hrs (Fig. 2C). The ability of DPDS 2 to induce cell cycle arrest
at the G0/G1 phase was corroborated in T-ALL MOLT-4 cells (Fig. 2D).
According to the Sanger Institute Catalogue of Somatic Mutations in
Table 1 GI50 values (lM) for DPDS 1-13
K-562 CCRF-CEM HT-29 PC-3 MCF-7 HTB-54 BEAS 184B5
1 8.73 9.81 5.71 1.64 8.78 20.34 0.05 1.51
2 1.91 0.30 8.71 1.97 5.89 3.10 0.62 0.07
3 7.11 6.36 0.95 0.04 10.94 21.40 0.04 0.06
4 8.75 13.50 6.83 1.12 8.36 28.76 0.002 0.18
5 1.00 2.12 22.68 4.33 6.66 6.53 2.83 2.69
6 3.18 2.38 9.42 4.57 4.61 3.27 15.79 2.93
7 6.98 6.68 6.36 4.30 4.52 5.41 4.03 5.08
8 9.30 9.27 14.31 10.23 10.47 29.57 6.77 5.99
9 20.3 19.42 24.54 24.42 16.06 31.06 17.29 3.39
10 13.7 2.71 10.33 7.01 5.16 24.06 6.38 5.39
11 5.57 2.04 19.73 6.13 8.43 26.62 9.24 5.24
12 8.55 1.69 15.75 3.87 7.24 16.04 22.54 5.14
13 12.9 2.67 14.91 9.33 12.56 26.44 10.11 5.84
Doxorubicin 0.10 <102 0.20 0.25 0.02 n.d 0.10 n.d
Camptothecin 0.06 n.d 0.05 0.06 0.01 n.d 0.06 n.d
Etoposide 12.5 1.58 31.62 0.63 19.95 n.d 12.5 n.d
Cisplatin 5.01 1.72 7.95 5.01 3.16 9.64 5.01 n.d
n.d.: not determined.
Fig. 2 DPDS 2 induces G0/G1 cell cycle arrest in CCRF-CEM cells. CCRF-CEM cells were exposed to 0.5, 1, 2 and 5 lM DPDS 2 or vehicle for
24 hrs. After incubation, cells were processed for propidium iodide staining, and their cellular DNA content was determined by flow cytometry. Posi-
tive controls contained camptothecin at the same concentration as DPDS 2. (A) Flow cytometry analysis of a representative experiment. (B) The
results are expressed as percentages of total cell counts. (C) Time course analysis of cell cycle phase distribution after incubation of the cells with
5 lM of DPDS 2. (D) Cell cycle phase distribution of MOLT-4 cell cultures after treatment with 20 lM DPDS 2 for 24 hrs. (E) Western blot analysis
of CDK4, p21CIP1 and p53 in CCRF-CEM cells treated with 2.5, 5 and 10 lM of compound DPDS 2 for 24 hrs. The results are the mean  S.E.M.
of at least three independent experiments. *P < 0.05 and **P < 0.01 compared with control cells.
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Cancer (COSMIC; http://www.sanger.ac.uk/cosmic), CCRF-CEM cells
carry a homozygous deletion of the CDKN2A locus (c.1_471del471),
which affects p16INK4, a CDK4-specific inhibitor. In contrast, wild-type
p53 down-regulates CDK4 translation [31]. Thus, to further examine
the mechanism by which DPDS 2-induced G0/G1 cell cycle arrest, the
expressions of CDK4, p14ARF, p53 and p21CIP1 proteins in CCRF-CEM
cells treated with 2.5, 5 or 10 lM DPDS 2 for 24 hrs were determined
by Western blot. Consistent with DPDS 2-mediated cell cycle arrest at
G0/G1, CDK4 expression was markedly decreased after the treatments
(Fig. 2E). In addition, treated CCRF-CEM cells exhibited increased
levels of p21CIP1 (Fig. 2E) and p53 (Fig. 2E) tumour suppressor pro-
teins, whereas p14ARF could not be detected in these CDNK2A-defec-
tive cells (not shown).
To assess the effect of DPDS 6 on cell cycle progression in lung
cells, HTB-54 cell cultures were exposed to 2, 5, 10, 15, 20 or 30 lM
DPDS 6 or vehicle (control cells) for 24 hrs, and the cell cycle phase
distribution of the cultures was determined as described above. A sig-
nificant decrease in the G0/G1 cell population and an increase in the
percentage of G2/M cells were detected after treatment with 5 lM or
greater DPDS 6 (Fig. 3A and B). Thus, these results suggest that
DPDS 6 induces cell cycle arrest in the late G2/M phase. Time course
analysis of cell cycle distribution upon treatment with 10 lM of DPDS
6 confirmed DPDS 6-mediated cell cycle arrest as soon as 8 hrs
(Fig. 3C). The ability of DPDS 6 to induce cell cycle arrest at G2/M in
lung cancer cells was confirmed in A549 cell cultures (Fig. 3D).
DPDS 2 triggers caspase-dependent apoptosis in
CCRF-CEM cells
Apoptosis forms the core of the anticancer effects displayed by Se
compounds [32]. Therefore, we sought to determine the role of apop-
tosis in the cytotoxicity exerted by both DPDS 2 and DPDS 6 in CCRF-
CEM and HTB-54 cells, respectively. Therefore, CCRF-CEM cells were
incubated in the presence or absence (control) of 0.5, 1, 2 or 5 lM
DPDS 2 for 24 hrs, and the apoptotic status of the cells was deter-
mined by measuring phosphatidylserine exposure on the cell mem-
branes using the Annexin V-FITC Kit. Camptothecin was used as a
positive control. The results are shown in Figure 4A and B. DPDS 2
triggered apoptosis in CCRF-CEM cells in a concentration-dependent
manner. Moreover, when cells were treated with 5 lM DPDS 2 for
different time periods, enhancement of cell death was detected as
early as 4 hrs, and the number of dead cells increased with time
(Fig. 4C). These results indicated that DPDS 2-mediated apoptosis is
also time dependent. Consistent with these results, blot analysis
demonstrated the accumulation of cleaved PARP in CCRF-CEM cells
after 4, 8 and 24 hrs of treatment with DPDS 2 (Fig. 4D). This
accumulation was observed at every DPDS 2 concentration tested.
Interestingly, BAX was also increased in CCRF-CEM cells after 24 hrs
of treatment with 10 lM DPDS 2 (Fig. 4E). Similarly, caspase-2, -3, -
8 and -9 (Fig. 4F) activity levels increased in CCRF-CEM cells after
treatment. In addition, pre-treatment of the cells with the pancaspase
inhibitor z-VAD-fmk protected both CCRF-CEM and MOLT-4 cells
from DPDS 2-induced apoptosis (Fig. 4G). However, pre-treatment
with the PI3K inhibitor wortmannin did not prevent DPDS 2-induced
cell death in these cells (Fig. 4G). Taken together, these results sug-
gest a prominent role for caspases in DPDS 2-mediated apoptosis in
T-ALL cells.
To test the ability of DPDS 6 to induce apoptosis, HTB-54 cells
were incubated in the presence or absence (control) of 2, 5, 10, 15,
20 or 30 lM DPDS 6 for 24 hrs, and the apoptotic status of the cells
was determined using the Apo-Direct Kit, which is based on the
TUNEL technique. As shown in Figure 5A and B, a slight increase in
DNA degradation was detected after treatment with 5 lM or higher
DPDS 6. In addition, this increase was concentration dependent but
not time dependent (Fig. 5C). Furthermore, the pro-apoptotic effects
of DPDS 6 were markedly reduced compared with those exerted by
camptothecin, even after incubation of HTB-54 cells with high doses
of DPDS 6 (10–30 lM) for 24 hrs (Fig. 5B) or for longer periods of
time (Fig. 5C). Finally, induction of cell death by DPDS 6 in HTB-54
cells could not be prevented by pre-treatment with the pancaspase
inhibitor z-VAD-fmk (Fig. 5D). Therefore, the data suggest that cas-
pase-dependent apoptosis is not the main cell death pathway involved
the cytotoxic effect triggered by DPDS 6 in HTB-54 cells.
DPDS 6 induces an autophagic cell death
process in HTB-54 cells
Autophagic cell death induction by some anticancer agents has been
proposed as a new cancer treatment modality [33, 34]. Hence, to fur-
ther analyse the molecular mechanism by which DPDS 6 reduced
HTB-54 cell viability, we explored the significance of autophagy in this
process. As shown in Figure 6A, a reduction in SQTMS1/p62 and
increased LC3-II levels [35] were detected in HTB-54 cells after expo-
sure to 5 lM or greater DPDS 6 for 24 hrs. In addition, pre-incuba-
tion of the cells with the autophagy inhibitors 3-MA, wortmannin and
CQ [36] markedly reduced DPDS 6-induced cell death (Fig. 6B).
Wortmannin also protected A549 cells from DPDS 6-induced cell
death (Fig. 6C). In contrast, wortmannin could not prevent induction
of CCRF-CEM cell death by DPDS 2 (Fig. 4G).
Given that JNK and p38 MAPK signallings are implicated in the
control of the balance of autophagy and apoptosis in response to
chemotherapeutic agents [37], we evaluated whether DPDS
Fig. 3 DPDS 6 induces G2/M cell cycle arrest in HTB-54 cells. HTB-54 cells were exposed to 2, 5, 10, 15, 20 and 30 lM DPDS 6 or vehicle for
24 hrs. After incubation, cells were processed for propidium iodide staining, and their cellular DNA content was determined by flow cytometry. Posi-
tive controls contained camptothecin at the same concentration as DPDS 6. (A) Flow cytometry analysis of a representative experiment. (B) The
results expressed as percentages of total cell counts. (C) Time course analysis of cell cycle phase distribution after incubation of the cells with
10 lM DPDS 6. (D) Cell cycle phase distribution of A549 cell cultures after treatment with 30 lM DPDS 6 for 24 hrs. The results are the
mean  S.E.M. of three independent experiments performed in duplicate. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with control cells.
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6-mediated autophagy involves JNK or p38 MAPK activation in HTB-
54 cells. JNK, p-JNK, p38 MAPK and p-p38 MAPK expression levels
were determined by Western blot in HTB-54 cells after treatment with
10 lM DPDS 6 for different time periods. As shown in Figure 6D and
E, increased levels of p38 and JNK were detected after 4 and 8 hrs,
respectively. However, although increased levels of p-JNK were
observed after 16 hrs of exposure to DPDS 6, a reduction in p-p38
MAPK was obvious at 4 hrs and remained low throughout the experi-
ment. In addition, pre-incubation of the cells with the broad-spectrum
JNK inhibitor SP600125-protected HTB-54 cells from DPDS 6-induced
autophagy (Fig. 6F). Taken together, these results suggest that DPDS
6 induces autophagic cell death in HTB-54 cells, which is characterized
by JNK up-regulation and p38 MAPK signalling inhibition.
Discussion
Converging lines of evidence demonstrate that Se compounds have
potential chemotherapeutic effects in a range of cancers. These deriva-
tives can be dosed in a variety of chemical forms, each of which may
display different anticancer mechanisms. In the present study, the anti-
cancer effects of novel DPDS derivatives were evaluated. In general,
most of the tested compounds exhibited potent cytotoxic effects
against a series of human cancer cell lines. Among the tested com-
pounds, derivatives 2 and 6 exhibited the most potent anticancer activ-
ity. Hence, we also explored the molecular mechanism involved in their
tumour-mediated cytotoxicity. We found that DPDS 2-induced apopto-
sis in leucemia CCRF-CEM cells, whereas autophagy was the main cell
death pathway triggered by DPDS 6 in HTB-54 lung cancer cells.
Currently, major efforts are focused on the design of strategies to
induce cell growth arrest and apoptosis selectively in tumour cells.
Numerous signals, including DNA damage and oxidative stress acti-
vate p53 [38]. Regardless of the signal, p53 activation might lead to
either cell cycle arrest via p21CIP1 transcription or to apoptosis by
inducing transcription of proteins, such as BAX, NOXA and PUMA
[39], and physically interacting with BCL-2 family members to pro-
mote mitochondrial outer membrane permeabilization [40]. Of note,
we observed increased levels of the p53 tumour suppressor protein
in T-ALL CCRF-CEM cells treated with DPDS 2. Although not fre-
quently noted at diagnosis, p53 mutations are associated with poor
clinical outcome in T-ALL [41]. Constitutive activation of NOTCH1 sig-
nalling and loss of the CDKN2A locus, which encompasses the cell
cycle regulators p16INK4 and p14ARF, is the most frequently reported
alterations implicated in the development of T-ALL [42]. In fact,
inactivation of the CDKN2A gene by deletion, mutation or promoter
hypermethylation is noted in up to 90% of T-ALL cases [41]. Epige-
netic inactivation of p21CIP1 has also been described in T-ALL sam-
ples [43]. As a result, the p53 pathway has been proposed as a
possible target for therapy in T-ALL [41]. Hence, our finding of
increased levels of the p53 protein in the CDNK2A-defective CCRF-
CEM cell line after treatment with DPDS 2 is of great relevance. Fur-
thermore, consistent with p53 up-regulation, we also observed G0/G1
cell cycle arrest at the G0/G1 phase and increased expression of the
p21CIP1 cell cycle regulator in CCRF-CEM cells after treatment with
DPDS 2. Given that we also observed increased expression of BAX
protein, our results indicate that DPDS 2 induces both cell cycle arrest
and activation of the intrinsic apoptotic pathway. Further supporting
the notion that DPDS 2 as an activator of the intrinsic apoptotic path-
way; enhanced caspase-9 activity and increased PARP cleavage were
detected in CCRF-CEM cells after treatment with this compound.
Additionally, caspase-8, an essential protease involved in the activa-
tion of the extrinsic apoptotic pathway, was also increased in DPDS
2-treated CCRF-CEM cells. This result might reflect different aspects
of the apoptotic process displayed by DPDS 2. Indeed, several studies
demonstrate that extrinsic and intrinsic pathways of caspase activa-
tion are extensively interconnected, and caspase-8 is activated by
caspase-9 in several experimental systems [44].
A common feature of organic Se compounds is that small
changes in their structure can lead to dramatic changes in their bio-
logical effects. Thus, it is not striking that compounds 2 and 6, which
are both DPDS analogues, displayed different mechanisms of action.
In fact, when tested in non-malignant BEAS-2B and HTB-54 non-small
lung cancer cells, DPDS 6 exhibited a strong toxicity and selectivity
for tumour cells. Given that HTB-54 is a p53 null cell line (http://p53.f
ree.fr), this result implies that DPDS 6 induces a cell death pro-
gramme that differs from p53-dependent apoptosis. Autophagy is a
conserved lysosomal degradation pathway that is involved in both
non-apoptotic tumour cell death and paradoxically tumour progres-
sion. In addition to apoptosis, induction of autophagy has been
described among the cellular and molecular mechanisms involved in
the anticancer activity of several seleno-compounds. For instance,
chronic exposure to supranutritional doses of sodium selenite
increase autophagy in normal colonic fibroblasts [45], whereas
autophagy and apoptosis are both engaged in selenite-induced cell
death in Jurkat [6] and NB4 [7] cells. Similar to other pro-autophagic
anticancer agents, DPDS 6 inhibited the cell cycle, induced a caspase-
independent cell death programme, reduced SQTMS1/p62 levels and
an increased LC3-II levels in HTB-54 cells. Moreover, the cytotoxic
Fig. 4 DPDS 2 induces caspase-dependent cell death in CCRF-CEM cells. CCRF-CEM cells were exposed to 0.5, 1, 2 and 5 lM DPDS 2 or vehicle for
24 hrs. After incubation, the rate of apoptotic cell death was determined by Annexin V-FITC staining. Positive controls contained camptothecin at the
same concentration as DPDS 2. (A) Flow cytometry analysis of a representative experiment. (B) The results expressed as percentages of apoptotic cells
in the cultures. (C) Time course analysis of DPDS 2-induced cell death; CCRF-CEM cells were treated with 5 lM DPDS 2 for different periods. (D) PARP
and (E) BAX protein levels in CCRF-CEM cells treated with 2.5, 5 and 10 lM DPDS 2 or vehicle for the indicated time periods were determined by Wes-
tern blot. (F) CCRF-CEM cells were incubated with either 5 lM DPDS 2 or vehicle (control cells) for 24 hrs. After incubation, caspase-2, -3, -8 and -9
activities were determined. Data are presented as the ratio between caspase activities in DPDS 2-treated and untreated cells. (G) For cell death inhibition
in CCRF-CEM and MOLT-4 cells, z-VAD-fmk (50 lM) and wortmannin (10 lM) were added to the culture medium 1 hr before DPDS 2 treatment. The
results are the mean  S.E.M. of three independent experiments. *P < 0.05 and **P < 0.01 compared with control cells.
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Fig. 5 DPDS 6-induced cell death in HTB-54 cell cultures is independent of caspase activation. HTB-54 cells were exposed to 2, 5, 10, 15, 20 and
30 lM DPDS 6 or vehicle for 24 hrs. After incubation, cell death was determined by TUNEL. Positive controls contained camptothecin at the same
concentration as DPDS 6. (A) Flow cytometry analysis of a representative experiment. (B) The results expressed as percentages of dead cells in the
cultures. Subdiploid cells were considered apoptotic. (C) Time course analysis of HTB-54 cell death after treatment with 10 lM DPDS 6. (D) HTB-
54 cells were pre-treated with 50 lM z-VAD-fmk for 1 hr and incubated with either 10 lM DPDS 6 or vehicle for 24 hrs before cell death determi-
nation. The results are the mean  S.E.M. of three independent experiments. *P < 0.05 and **P < 0.01 compared with control cells.
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Fig. 6 DPDS 6 induces autophagy in HTB-54 cells. (A) Western blot analysis of SQTMS1/p62 and LC3 in HTB-54 cells treated with 2.5, 5 and
10 lM DPDS 6 or vehicle for 24 hrs. (B) HTB-54 cells pre-treated with 5 mM 3-MA, 10 lM wortmannin or 10 lM CQ for 1 hr were incubated with
either 10 lM DPDS 6 or vehicle for 24 hrs. Then, cell death was determined by TUNEL. (C) Cell death determination in A549 cell cultures after
exposure to 30 lM DPDS 6 either in the presence or absence of 10 lM wortmannin. (D) Time course analysis of p38 and p-p38 MAPK expression
in HTB-54 cells exposed to 10 lM DPDS 6. (E) Time course analysis of JNK and p-JNK expression in HTB-54 cells exposed to 10 lM of DPDS 6.
(F) HTB-54 cells pre-treated with 10 lM SP600125 for 1 hr were incubated with 10 lM DPDS 6 or vehicle for 24 hrs. Then, cell death was deter-
mined by TUNEL. The results are the mean  S.E.M. of three independent experiments. *P < 0.05 and **P < 0.01 compared with control cells.
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effects of DPDS 6 in HTB-54 cells were abolished by the presence of
PI3K inhibitors (3-MA or wortmannin) or a lysosomotropic agent
(CQ) [36], thus suggesting a pivotal role for autophagy in the anti-
cancer effects exerted by DPDS 6. Although crosstalk between autop-
hagy and apoptosis has not been completely deciphered, several lines
of evidence suggest that both pathways are interconnected and even
simultaneously activated in neoplastic cells [15]. In fact, concurrent
apoptosis and autophagy have been detected in selenite-treated colon
cancer cells. Interestingly, both basal and selenite-induced autophagy
levels varied depending on the p53 status of the cells. These levels
were increased when this protein was deleted [23]. Thus, our finding
that DPDS 6 induces autophagy in p53 null HTB-54 lung cancer cells
is not surprising.
Over recent years, several reports have implicated JNK and p38
MAPK pathways in regulating the balance between apoptosis and
autophagy in response to chemotherapeutic agents [17, 37, 45–47].
p38 MAPK has a dual role as an activator and inhibitor of autophagy
[37]. When activated by the GADD45B-MAP3K4 signalling complex,
p38 MAPK is directed to autophagosomes where it phosphorylates
Atg5, impairing autophagy [48]. A direct competition between Atg9, a
transmembrane protein required for autophagy, and p38 MAPK for
binding to p38 IP was also reported to inhibit autophagy [46]. In con-
trast, JNK1 activation under starvation conditions promotes Bcl-2/
Bcl-xL phosphorylation, which results in the release of Beclin 1 from
the Beclin 1-Bcl-2/Bcl-xL complex. At first, the liberation of Beclin 1
up-regulates LC3 and stimulates autophagy. After prolonged phos-
phorylation, autophagy can no longer protect cells, and apoptosis is
induced [17, 49]. Interestingly, sodium selenite anticancer effects are
associated with JNK activation in colon cancer cell lines [8] and p38
MAPK modulation in Jurkat and NB4 cells [6, 7]. Modulation of p38
MAPK activity using a combination of aspirin and ABT-737 has also
been demonstrated in A549 and H1299 lung cancer cells [47]. Con-
sistent with these observations, we demonstrated a reduction in
p-p38 MAPK and an increase in p-JNK levels in HTB-54 cells after
treatment with DPDS 6. Furthermore, SP600125, a compound that
inhibits JNK phosphorylation in Jurkat T cells [50] and induces p38
MAPK phosphorylation in mouse pancreatic beta cells MIN6 [51], pre-
vented induction of autophagy by DPDS-6. Our results thus suggest
that DPDS 6 triggers autophagic cell death in p53-deficient lung can-
cer cells through the modulation of p38 MAPK and JNK signalling
pathways. The potent anticancer effects and the ability of DPDS 6 to
spare non-malignant cells suggest that the balance between apoptosis
and autophagy is optimal under these experimental circumstances.
Regarding the structure-activity relationship of this compound, a
recent study proposes the N,N0-diarylurea motif as a potent p38 MAPK
inhibitor [52]. However, further experiments, including the design and
synthesis of structurally modified DPDS 6 derivatives are required to
dissect the role of Se and N,N0-diarylurea motifs in the regulation of
JNK and p38 MAPK pathways by this compound.
In summary, the present study demonstrates the anticancer activ-
ity of a variety of novel DPDS derivatives. Overall, these compounds
displayed potent in vitro cytotoxic effects against tumour cells. DPDS
2 and 6, which are the most potent derivatives, exhibited strong anti-
cancer activities through the induction of apoptosis and autophagy,
respectively. When using normal and lung cancer cell lines, DPDS 6
also displayed a strong selectivity for p53-deficient cell lines, where it
modulates JNK and p38 MAPK activities. Whether DPDS 6 adminis-
tration could result in a better outcome in the treatment of impaired
p53-bearing lung cancer cells merits further research.
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